Cancer/Tumor Profiling Market Overview:
Cancer/tumor profiling is the process of studying the genetic makeup of a cancerous tumor in order to better understand its behavior and develop targeted treatments
In recent years, cancer treatment options have advanced significantly. From the initial surgical procedures to the most advanced next-generation technologies, we are now in a position to analyze and understand tumors on an individual basis, allowing us to provide individualized treatment options that may increase patient survival. In this review, we will look at how tumor profiling has changed over the years to provide more efficient and personalized treatment options, as well as how novel technologies can help us envision the future of precision oncology toward better management and, ultimately, increased survival.
According to a recent report by Emergen analysis, the Cancer/Tumor Profiling Market is anticipated to reach USD.ninety nine billion by then. The growth of this market is related to the increased use of biomarkers in melanoma profiling, which is followed by an increase in the use of proteomic techniques for biomarker analysis, helping to expand the biologic building system over the anticipated time period. The changing consumer preference for customised medications and the increase in melanoma incidents worldwide are driving the demand for the sector. According to the global health organisation WHO, Lung and Breast cancer is a common type of melanoma, with around. actor cases per year. The predicted length is driving the industry as cancer bump profiling’s popularity begins to grow.
During the forecast period, the cancer tumour profiling market is expected to grow at a CAGR of 12.75%. This means that the market value, which was $9.35 billion in 2021, will skyrocket to $24.44 billion by 2029.
Report Scope
| Report Metric | Details |
| Market size available for years | 2022–2029 |
| Base year considered | 2021 (Accessible in 2019 – 2014) |
| Forecast period | 2020–2027 |
| CAGR | ~12.75% CAGR(2022-2029) |
| Forecast unit | Value (USD billion) |
| Segments covered | Type of Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer), Type of Biomarker (Genomic Biomarker, Protein Biomarker), Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays, and Other Technologies (Genomics, Proteomics, Metabolomics, Epigenetics), Application (Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening, Treatment and Monitoring) (Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening, Treatment and Monitoring) |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Diagnostics (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq(US), Histogene X (Belgium) |
An overview of the global Cancer/Tumor Profiling market, and related technologies and developments. Analyses of global market trends, with historical data from 2018, 2019, and 2020 estimates and projections of CAGRs through 2029. It also includes breakdowns of the overall Cancer/Tumor Profiling market along with various segments, and by geographic region. Analysis of the stakeholder value chain in the Cancer/Tumor Profiling market and comprehensive profiles of leading companies in the industry.
Report Scope
The report forecasts the size of the Cancer/Tumor Profiling market for components from 2020 through 2027
The Executive Summary provides a snapshot of key findings of the report. The introduction chapter includes research scope, market segmentation, research methodology, and definitions and assumptions. It involves extreme rigorous scientific methods, tools and techniques to estimate the market size. Exhaustive secondary research is being carried out to collect information related to the market, the parent market, and the peer market. Primary research is undertaken to validate the assumptions, findings, and sizing with the industry experts professionals across the value chain of the market. Both top-down and bottom-up approaches are employed to estimate the complete market size.
Cancer type, biomarker type, technology, technique, and application are the segments of the cancer tumour profiling market. The growth in these segments will assist you in analyzing meager growth segments in industries and providing users with a valuable market overview and market insights to assist them in selecting the primary market applications while making strategic decisions.
Cancer type
· Colorectal Cancer
· Prostate Cancer
· Melanoma Cancer
· Breast Cancer
· Lung Cancer
· Other Cancer
Biomarker type
· Protein Biomarker
· Genomic Biomarker
Technology
· Genomics
· Proteomics
· Metabolomics
· Epigenetics
Application
· Research
· Biomarker Discovery
· Personalized Medicine
· Clinical Application
· Diagnostics
· Prognostics
· Screening
· Treatment and Monitoring
Global Cancer/Tumor Profiling market Competitive Analysis:
Key players in the Global Cancer/Tumor Profiling market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Diagnostics (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq(US), Histogene X (Belgium).
*All our reports are customizable as per customer requirements
This study forecasts revenue and volume growth at global, regional, and country levels from 2018 to 2029. The global Cancer/Tumor Profiling market is distributed on the basis of below-mentioned segments:
Global Cancer/Tumor Profiling market, By Types Segment:
- Next-generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- Microarray
- OthersGlobal Cancer/Tumor Profiling market, By Application Segment :
- Personalized Medicine
- Diagnostics
- Biomarker Discovery
- Prognostics
- Research Applications
- Others
Global Cancer/Tumor Profiling market, By Region:
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
Table of Content
1. Introduction
2. Executive Summary
3. Market Dynamics
4. Key Insights
5. Global Cancer/Tumor Profiling Market Analysis (USD Billion), Insights and Forecast, 2016-2027
6. North America Cancer/Tumor Profiling Market Analysis (USD Billion), Insights and Forecast, 2016-2027
7. Latin America Cancer/Tumor Profiling Market Analysis (USD Billion), Insights and Forecast, 2016-2027
8. Europe Cancer/Tumor Profiling Market Analysis (USD Billion), Insights and Forecast, 2016-2027
9. Asia Pacific Cancer/Tumor Profiling Market Analysis (USD Billion), Insights and Forecast, 2016-2027
10. Middle East & Africa Cancer/Tumor Profiling Market Analysis (USD Billion), Insights and Forecast, 2016-2027
11. Competitive Analysis